National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

Last updated: June 15, 2025
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Hematological Disorders

Red Blood Cell Disorders

Treatment

A combined retrospective and prospective observational follow-up

Clinical Study ID

NCT07019766
IIT2025043
  • All Genders

Study Summary

Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology.

The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China.

  1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors.

  2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics

  3. Assess treatment patterns and real-world effectiveness in LGLL patients.

  4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality

  5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects diagnosed with LGLL.

  • Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.

Exclusion

Exclusion Criteria:

  • Subject unlikely to be available for long-term follow-up for any reason (e.g.,inability to obtain follow-up data or presence of severe comorbidities).

  • Subject with alcohol or drug dependence that may reduce their compliance with thestudy.

  • Subjects that the investigator believes have other reasons that make them unsuitablefor inclusion in this study.

Study Design

Total Participants: 9999
Treatment Group(s): 1
Primary Treatment: A combined retrospective and prospective observational follow-up
Phase:
Study Start date:
January 01, 2000
Estimated Completion Date:
December 31, 2070

Connect with a study center

  • Red Blood Cell Diseases Center and Regenerative Medicine Center

    Tianjin, Tianjin 301617
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.